HUTCHMED files cancer application: BofA targets HUTCHMED stock at USD 18.00

Published on 10/02/2026 at 13:27 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

SAFFRON enrolled 338 patients at 230 centers in 29 countries. HUTCHMED stock costs EUR 12.90 on October 2, 2026 after EUR 13.00, minus 0.77 percent.

HCM, US44842L1035, Illustration mit AI erstellt.

HUTCHMED (ISIN US44842L1035) was trading at EUR 12.90 at Lang & Schwarz on October 2, 2026 at 1:16 p.m. CEST, down 0.77 percent versus the prior close of EUR 13.00. The company filed a US cancer application, while Markets Insider reported on September 21, 2026 that BofA raised its HUTCHMED target from USD 16.00 to USD 18.00 and kept a Buy rating.

FDA filing covers 338 patients

According to GlobeNewswire on September 28, 2026, AstraZeneca submitted the application to the US Food and Drug Administration for ORPATHYS plus TAGRISSO in patients with MET-driven, EGFR-mutated non-small cell lung cancer. The filing is supported by the global SAFFRON Phase III trial, which enrolled 338 patients at 230 centers in 29 countries.

The trial showed statistically significant and clinically meaningful improvements in progression-free survival and overall survival against doublet platinum-based chemotherapy, according to the same company release. The data are scheduled for presentation in a Presidential Symposium at the European Society for Medical Oncology Congress 2026.

Revenue missed the consensus estimate

HUTCHMED's latest reported quarter also shows why regulatory progress matters. For the second quarter of 2026, revenue was USD 139.14 million and diluted earnings per share were USD 0.05, according to MarketBeat on September 18, 2026. Revenue was below the USD 304.16 million consensus estimate, while earnings per share missed the USD 0.14 estimate.

The contrast is material: the clinical pipeline produced a new regulatory milestone, but the latest quarter delivered only 45.74 percent of the revenue consensus. That makes the US review and commercial execution important counterweights to the earnings miss.

Analyst target reaches USD 18.00

BofA's September 21, 2026 target of USD 18.00 compares with the USD 16.00 previous target, a 12.50 percent increase. The target remains above the seven-analyst average of USD 14.87 reported by MarketBeat on September 18, 2026, where the overall rating was Hold.

Investing.com lists HUTCHMED's next results date as November 13, 2026. The Nasdaq listing's 52-week range was USD 9.77 to USD 16.40 as of October 1, 2026, while market capitalization was USD 2.5 billion.

HUTCHMED stock trades at EUR 12.90

HUTCHMED stock was trading at EUR 12.90 at Lang & Schwarz on October 2, 2026 at 1:16 p.m. CEST, down 0.77 percent versus the Lang & Schwarz prior close of EUR 13.00. The Nasdaq ticker HCM was listed at USD 14.57 on October 1, 2026 at 8:00 p.m. UTC, before the October 2, 2026 US session.